Cholesterol efflux regulatory protein, Tangier disease and familial high density lipoprotein deficiency

Current Opinion in Lipidology

Volumn 11, Issue 2, 2000, Pages 117-122

  Hayden, Michael R ^a   Clee, Susanne M ^a   Brooks Wilson, Angela ^a,e   Genest Jr , Jacques ^b   Attie, Alan ^c   Kastelein, John J P ^d  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Xenon Bioresearch Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER A1; CHOLESTEROL; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

CELL TRANSPORT; CHOLESTEROL TRANSPORT; GENE MUTATION; HUMAN; LIVER; PRIORITY JOURNAL; REVIEW; TANGIER DISEASE;

ATP-BINDING CASSETTE TRANSPORTERS; CHOLESTEROL; HUMANS; LIPOPROTEINS, HDL; MODELS, BIOLOGICAL; TANGIER DISEASE;

EID: 0034085567     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200004000-00003     Document Type: Review

References (32)

1. 1 Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J Lipid Res 1968; 9:155-167.
2. 2 Oram JF, Yokoyama S. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996; 37:2473-2491.
3. 3 Rothblat GH, Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40:781-796. This is an excellent and comprehensive review of the various mechanisms whereby cholesterol efflux may occur, tying together the findings of numerous biochemical studies.
4. 4 Forte TM, Bielicki JK, Goth-Goldstein R, Selmek J, McCall MR. Recruitment of cell phospholipids and cholesterol by apolipoproteins A-II and A-I: formation of nascent apolipoprotein-specific HDL that differ in size, phospholipid composition, and reactivity with LCAT. J Lipid Res 1995; 36:148-157.
5. 5 Zhao Y, Sparks DL, Marcel YL. Specific phospholipid association with apolipoprotein A-I stimulates cholesterol efflux from human fibroblasts. Studies with reconstituted sonicated lipoproteins. J Biol Chem 1996; 271:25145-25151.
6. 6 Yancey PG, Bielicki JK, Johnson WJ, Lund-Katz S, Palgunachari MN, Anantharamaiah GM, et al. Efflux of cellular cholesterol and phospholipid to lipid-free apolipoproteins and class A amphipathic peptides. Biochemistry 1995; 34:7955-7965.
7. 7 Oikawa S, Mendez AJ, Oram JF, Bierman EL, Cheung MC. Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracelluiar cholesterol efflux. Biochim Biophys Acta 1993; 1165:327-334.
8. 8 Davidson WS, Gillotte KL, Lund-Katz S, Johnson WJ, Rothblat GH, Phillips MC. The effect of high density lipoprotein phospholipid acyl chain composition on the efflux of cellular free cholesterol. J Biol Chem 1995; 270:5882-5890.
9. 9 Fournier N, Paul JL, Atger V, Cogny A, Soni T, Llera-Moya M, et al. HDL phospholipid content and composition as a major factor determining cholesterol efflux capacity from Fu5AH cells to human serum. Arterioscler Thromb Vasc Biol 1997; 17:2685-2691.
10. 10 Brooks-Wilson A, Marcil M, Clee SM, Zhang LH, Roomp K, van Dam M, et al. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nature Genet 1999; 22:336-345. The strengths of genetics are illustrated in this paper, which independently identified the ABC1 gene as underlying both Tangier disease and FHA, a related disorder. This was the first demonstration that these two disorders are in fact allelic.
11. 11 Rust S, Rosier M, Funke H, Real J, Amoura Z, Piette JC, et al. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nature Genet 1999; 22:352-355. This is a cloning effort leading to the identification of the ABC1 gene in Tangier Disease, which is notable for its identification of the mutation in the original Tangier disease probands.
12. 12 Bodzioch M, Orso E, Klucken J, Langmann T, Bottcher A, Diederich W, et al. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nature Genet 1999; 22:347-351. On the basis of the identification of macrophage genes regulated by HDL, this paper identifies mutations in ABC1 as the cause of Tangier disease in five families. The biochemical approach lends much insight into potential functions of CERP.
13. 13 Gillotte KL, Zaiou M, Lund-Katz S, Anantharamaiah GM, Holvoet P, Dhoest A, et al. Apolipoprotein-mediated plasma membrane microsolubilization. Role of lipid affinity and membrane penetration in the efflux of cellular cholesterol and phospholipid. J Biol Chem 1999; 274:2021-2028.
14. 14 Han H, Sasaki J, Matsunaga A, Hakamata H, Huang W, Ageta M, et al. A novel mutant, ApoA-I nichinan (Glu235->0), is associated with low HDL cholesterol levels and decreased cholesterol efflux from cells. Arterioscler Thromb Vasc Biol 1999; 19:1447-1455.
15. 15 Daum U, Leren TP, Langer C, Chirazi A, Cullen P, Pritchard PH, et al. Multiple dysfunctions of two apolipoprotein A-I variants, apoA-I(R160L)Oslo and apoA-I(P165R), that are associated with hypoalphalipoproteinemia in heterozygous carriers. J Lipid Res 1999; 40:486-494.
16. 16 Daum U, Langer C, Duverger N, Emmanuel F, Benoit P, Denefle P, et al. Apolipoprotein A-I (R151C)Paris is defective in activation of lecithin:cholesterol acyltransferase but not in initial lipid binding, formation of reconstituted lipoproteins, or promotion of cholesterol efflux. J Mol Med 1999; 77:614-622.
17. 17 Gillotte KL, Davidson WS, Lund-Katz S, Rothblat GH, Phillips MC. Apolipoprotein A-I structural modification and the functionality of reconstituted high density lipoprotein particles in cellular cholesterol efflux. J Biol Chem 1996; 271:23792-23798.
18. 18 Lindstedt L, Saarinen J, Kalkkinen N, Welgus H, Kovanen PT. Matrix metalloproteinases-3, -7, and -12, but not -9, reduce high density lipoprotein-induced cholesterol efflux from human macrophage foam cells by truncation of the carboxyl terminus of apolipoprotein A-I. Parallel losses of pre-beta panicles and the high affinity component of efflux. J Biol Chem 1999; 274:22627-22634. This study presents a novel mechanism whereby cholesterol-loaded cells may be inhibited in their attempts to efflux cholesterol.
19. 19 Mendez AJ, Anantharamaiah GM, Segrest JP, Oram JF. Synthetic amphipathic helical peptides that mimic apolipoprotein A-I in clearing cellular cholesterol. J Clin Invest 1994; 94:1698-1705.
20. 20 Wolfbauer G, Albers JJ, Oram JF. Phospholipid transfer protein enhances removal of cellular cholesterol and phospholipids by high-density lipoprotein apolipoproteins. Biochim Biophys Acta 1999; 1439:65-76.
21. 21 Rashduni DL, Rifici VA, Schneider SH, Khachadurian AK. Glycation of high-density lipoprotein does not increase its susceptibility to oxidation or diminish its cholesterol efflux capacity. Metabolism 1999; 48:139-143.
22. 22 Kronqvist R, Leppimaki P, Mehto P, Slotte JP. The effect of interleukin 1 beta on the biosynthesis of cholesterol, phosphatidylcholine, and sphingomyelin in fibroblasts, and on their efflux from cells to lipid-free apolipoprotein A-I. Eur J Biochem 1999; 262:939-946.
23. 23 Sakr SW, Williams DL, Stoudt GW, Phillips MC, Rothblat GH. Induction of cellular cholesterol efflux to lipid-free apolipoprotein A-I by cAMP. Biochim Biophys Acta 1999; 1438:85-98.
24. 24 Oram JF, Mendez AJ, Lymp J, Kavanagh TJ, Halbert CL. Reduction in apolipoprotein-mediated removal of cellular lipids by immortalization of human fibroblasts and its reversion by cAMP: lack of effect with Tangier disease cells. J Lipid Res 1999; 40:1769-1781.
25. 25 Takahashi Y, Smith JD. Cholesterol efflux to apolipoprotein AI involves endocytosis and resecretion in a calcium-dependent pathway. Proc Natl Acad Sci USA 1999; 96:11358-11363. This intriguing study suggested a novel intracellular mechanism whereby apolipoprotein AI becomes associated with cholesterol.
26. 26 Ji Y, Jian B, Wang N, Sun Y, Moya ML, Phillips MC, et al. Scavenger receptor BI promotes high density lipoprotein-mediated cellular cholesterol efflux. J Biol Chem 1997; 272:20982-20985.
27. 27 Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weibel G, Sakr SW, Phillips MC, Williams DL. Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 1999; 40:575-580.
28. 28 Rust S, Walter M, Funke H, von Eckardstein A, Cullen P, Kroes HY, et al. Assignment of Tangier disease to chromosome 9q31 by a graphical linkage exclusion strategy. Nature Genet 1998; 20:96-98.
29. 29 Marcil M, Yu L, Krimbou L, Boucher B, Oram JF, Cohn JS, Genest Jr J. Cellular cholesterol transport and efflux in fibroblasts are abnormal in subjects with familial HDL deficiency. Arterioscler Thromb Vasc Biol 1999; 19:159-169.
30. 30 Marcil M, Brooks-Wilson A, Clee SM, Roomp K, Zhang LH, Yu L, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999; 354:1341-1346. The demonstration of mutations in FHA families of different ancestries in this paper firmly establishes the presence of a phenotype in individuals heterozygous for mutations in the ABC1 gene, and is the first data to show that mutations in ABC1 are a major cause of efflux defects in humans.
31. 31 Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, et al. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest 1999; 104:R25-R31. This paper illustrates the power of combined power of expression analysis and genetic mapping, and provides additional biochemical data that illustrate the role and regulation of CERP in the cholesterol efflux pathway.
32. 32 van Driel MA, Maugeri A, Klevering BJ, Hoyng CB, Cremers FP. ABCR unites what ophthalmologists divide(s). Ophthalmic Genet 1998; 19:117-122.